Carlo Marchetti
Overview
Explore the profile of Carlo Marchetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1955
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tengesdal I, Banks M, Dinarello C, Marchetti C
Front Immunol
. 2024 Aug;
15:1422249.
PMID: 39188718
Decades of evidence positioned IL-1β as a master regulatory cytokine in acute and chronic inflammatory diseases. Approved biologics aimed at inhibiting IL-1 signaling have shown efficacy but variable safety. More...
2.
Da Prat V, Aretano L, Moschini M, Bettiga A, Crotti S, De Simeis F, et al.
Healthcare (Basel)
. 2024 Mar;
12(6).
PMID: 38540660
Radical cystectomy (RC) with pelvic lymph node dissection is the standard treatment for patients with limited-stage muscle-invasive bladder cancer. RC is associated with a complication rate of approximately 50-88%. Immunonutrition...
3.
Gaballa J, Falkesgaard Hojen J, de Graaf D, Amo-Aparicio J, Marchetti C, Cavalli G, et al.
Nat Immunol
. 2024 Mar;
25(4):581-582.
PMID: 38499798
No abstract available.
4.
Pham-Danis C, Chia S, Scarborough H, Danis E, Nemkov T, Kleczko E, et al.
bioRxiv
. 2024 Mar;
PMID: 38496448
Background: Lung cancer is the leading cause of cancer death in the world. While cigarette smoking is the major preventable factor for cancers in general and lung cancer in particular,...
5.
Dinarello A, May M, Amo-Aparicio J, Azam T, Gaballa J, Marchetti C, et al.
Proc Natl Acad Sci U S A
. 2023 Oct;
120(45):e2306476120.
PMID: 37906644
The IL-1 Family member IL-38 has been characterized primarily as an antiinflammatory cytokine in human and mouse models of systemic diseases. Here, we examined the role of IL-38 in the...
6.
Tengesdal I, Dinarello C, Marchetti C
Pharmacol Ther
. 2023 Oct;
251:108545.
PMID: 37866732
More than a decade ago IL-1 blockade was suggested as an add-on therapy for the treatment of cancer. This proposal was based on the overall safety record of anti-IL-1 biologics...
7.
Amo-Aparicio J, Dominguez A, Atif S, Dinarello A, Azam T, Alula K, et al.
Cancer Res Commun
. 2023 Sep;
3(9):1899-1911.
PMID: 37772994
Significant: This study provides novel molecular insights on how PDAC cells exploit NLRP3 activation to suppress CD8 T-cell activation. From a translational perspective, we demonstrate that the combination of gemcitabine...
8.
de Graaf D, Wang R, Amo-Aparicio J, Lee J, Dowdell A, Tengesdal I, et al.
Front Immunol
. 2022 Jun;
13:840719.
PMID: 35693797
IL-38 is a recently discovered cytokine and member of the IL-1 Family. In the IL-1 Family, IL-38 is unique because the cytokine is primarily a B lymphocyte product and functions...
9.
Tengesdal I, Li S, Powers N, May M, Neff C, Joosten L, et al.
Pharmaceuticals (Basel)
. 2022 May;
15(5).
PMID: 35631400
Tumor-associated inflammation leads to dysregulated cytokine production that promotes tumor immune evasion and anti-tumor immunity dysfunction. In advanced stage breast cancer, the proinflammatory cytokine IL-1β is overexpressed due to large...
10.
Tengesdal I, Dinarello A, Powers N, Burchill M, Joosten L, Marchetti C, et al.
Front Immunol
. 2021 Sep;
12:661323.
PMID: 34531850
Tumors evade the immune system by inducing inflammation. In melanoma, tumor-derived IL-1β drives inflammation and the expansion of highly immunosuppressive myeloid-derived suppressor cells (MDSCs). Similar in many tumors, melanoma is...